Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., . . . Yin, W. (2022). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infectious Diseases, 22(4), 483-496.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Zeng, Gang, et al. "Immunogenicity and Safety of a Third Dose of CoronaVac, and Immune Persistence of a Two-dose Schedule, in Healthy Adults: Interim Results from Two Single-centre, Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trials."
Lancet Infectious Diseases 22, no. 4 (2022): 483-496.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Zeng, Gang, et al. "Immunogenicity and Safety of a Third Dose of CoronaVac, and Immune Persistence of a Two-dose Schedule, in Healthy Adults: Interim Results from Two Single-centre, Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trials."
Lancet Infectious Diseases, vol. 22, no. 4, 2022, pp. 483-496.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.